{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:39:42Z","timestamp":1782167982724,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jviromet.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T12:57:45Z","timestamp":1542286665000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay"],"prefix":"10.1016","volume":"264","author":[{"given":"Wildeberg C\u00e1l","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia S.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica F.S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Eug\u00eanio Castro Cardoso","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wlamir Corr\u00eaa de","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2018.11.005_bib0005","first-page":"135","article-title":"Potential application of the consistency approach for vaccine potency testing","volume":"134","author":"Arciniega","year":"2012","journal-title":"Dev. Biol. (Basel)"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0010","series-title":"Laboratory Techniques in Rabies","first-page":"265","article-title":"The antibody-binding test for vaccine potency","author":"Arko","year":"1973"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0015","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1128\/JVI.65.8.4198-4203.1991","article-title":"Antigenicity of rabies virus glycoprotein","volume":"65","author":"Benmansour","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0020","series-title":"Instructions for the Control of the Production and Marketing of Vaccines and Anti-rabies Serum for veterinary use]. Instru\u00e7\u00f5es referentes ao Controle da Produ\u00e7\u00e3o e Comercializa\u00e7\u00e3o de Vacinas e Soro Anti-r\u00e1bico para uso veterin\u00e1rio","article-title":"Minist\u00e9rio da Agricultura Pecu\u00e1ria e Abastecimento. Portaria no 228, de 25 de outubro de","author":"Brasil","year":"1988"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0025","first-page":"1366","volume":"vol. 2","author":"Brasil","year":"2010"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0030","first-page":"1297","volume":"vol. 2","author":"Brasil","year":"2010"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/026119290303100409","article-title":"Three Rs approaches in the quality control of inactivated rabies vaccines","volume":"31","author":"Bruckner","year":"2003","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","article-title":"G-protein based ELISA as a potency test for rabies vaccines","volume":"46","author":"Chabaud-Riou","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0045","series-title":"The European Pharmacopoeia. Rabies Vaccine (inactivated) for Veterinary Use","first-page":"1008","author":"Council of Europe","year":"2013"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0050","series-title":"The European Pharmacopoeia. Rabies Vaccine for Human Use Prepared in Cell Cultures","first-page":"3952","author":"Council of Europe","year":"2015"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0055","first-page":"281","article-title":"Rabies reference vaccine for use as a regional standard for Latin America and the Caribbean countries","volume":"18","author":"Diaz","year":"1990","journal-title":"Biobgicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0060","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/JVI.64.8.3804-3809.1990","article-title":"Structural and immunological characterization of a linear virus neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0065","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.biologicals.2011.08.002","article-title":"Antigen content versus volume of rabies vaccines administered intradermally","volume":"39","author":"Dodet","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0070","series-title":"Laboratory Techniques in Rabies","first-page":"378","article-title":"Single radial immunodiffusion test for the determination of the glycoprotein content of inactivated rabies vaccines","author":"Ferguson","year":"1996"},{"issue":"1","key":"10.1016\/j.jviromet.2018.11.005_bib0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1099\/0022-1317-59-1-197","article-title":"A single-radial-immunodiffusion technique for the assay of rabies glycoprotein antigen: application to potency tests of vaccines against rabies","volume":"59","author":"Ferguson","year":"1982","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0080","series-title":"Probit Analysis","author":"Finney","year":"1971"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0085","first-page":"183","article-title":"Use of the antibody assay in immunized mice for the determination of rabies vaccine potency","volume":"40","author":"Fitzgerald","year":"1978","journal-title":"Develop Biol Standard"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1045-1056(02)00070-2","article-title":"Inactivated rabies vaccine control and release: use of an ELISA method","volume":"31","author":"Fournier-Caruana","year":"2003","journal-title":"Biol"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/biol.1996.0012","article-title":"Use of ELISA for in vitro potency test of rabies vaccines for animal use","volume":"24","author":"Gamoh","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0100","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2013.10.019","article-title":"A relevant in vitro ELISA test in alternative to the in vivo NIH test forhuman rabies vaccine batch release","volume":"31","author":"Gibert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0105","first-page":"140","article-title":"Habeltest for potency","volume":"vol. 23","author":"Habel","year":"1966"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0110","series-title":"Internet]. International Committee on Taxonomy of Viruses - ICTV [cited 2017 Sep 01]","author":"ICTV 9th Report","year":"2011"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JVI.73.1.225-233.1999","article-title":"Chimeric lyssavirus glycoproteins with increased immunological potential","volume":"73","author":"Jallet","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1637\/11143-050815-Reg","article-title":"A Dose-Response Study of Inactivated Low Pathogenic Avian Influenza H9N2 Virus in Specific-Pathogen-Free and Commercial Broiler Chickens Walid H","volume":"60","author":"Kilany","year":"2016","journal-title":"Avian Dis."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.biologicals.2009.01.001","article-title":"The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines","volume":"37","author":"Kr\u00e4mer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0130","first-page":"37","article-title":"Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use","volume":"2","author":"Kr\u00e4mer","year":"2010","journal-title":"Pharmeur Biol Sci Notes"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0135","first-page":"291","article-title":"Consistency testing of diphtheria and tetanus to replace potency testing for lot release","volume":"111","author":"Kreeftenberg","year":"2002","journal-title":"Dev. Biol. (Basel)"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1348-0421.1998.tb02270.x","article-title":"Antigenic and functional analyses of glycoprotein of rabies virus using monoclonal antibodies","volume":"42","author":"Luo","year":"1998","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0145","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/S0264-410X(03)00249-4","article-title":"Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines","volume":"21","author":"Maas","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0150","series-title":"Field\u2019s Virology","first-page":"1245","article-title":"Rhabdoviruses","author":"Mattos","year":"2001"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jviromet.2018.10.003","article-title":"Development and pre-validation of a quantitative multi-dose serological assay for potency testing of inactivated rabies vaccines for human use","volume":"263","author":"Moreira","year":"2019","journal-title":"Journal of Virological Methods January"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0160","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.vaccine.2016.12.039","article-title":"Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA \u2013 results of an international collaborative study","volume":"35","author":"Morgeaux","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2008.09.010","article-title":"Validation of a virus neutralization potency test in BHK-21 cells for rabies immunoglobulins in a two-center study","volume":"54","author":"Moura","year":"2008","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biologicals.2005.07.004","article-title":"A simple immuno-capture ELISA to estimate rabies viral glyco-protein antigen in vaccine manufacture","volume":"34","author":"Nagarajan","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0175","series-title":"Laboratory Techniques in Rabies Geneva","first-page":"383","article-title":"Enzyme linked immuno-sorbent assay (ELISA) for the determination of glycoprotein content of rabies vaccines","author":"Perrin","year":"1996"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/1045-1056(90)90037-Z","article-title":"In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing antiglycoprotein monoclonal antibody","volume":"18","author":"Perrin","year":"1990","journal-title":"Biologicals"},{"issue":"2","key":"10.1016\/j.jviromet.2018.11.005_bib0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1590\/S0074-02762002000200022","article-title":"Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle","volume":"97","author":"Piza","year":"2002","journal-title":"Mem Inst Oswaldo Cruz March"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0190","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.vaccine.2012.11.069","volume":"31","author":"Romstad","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0195","first-page":"137","article-title":"Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines","volume":"86","author":"Rooijakkers","year":"1996","journal-title":"Dev. Biol. Stand."},{"issue":"February","key":"10.1016\/j.jviromet.2018.11.005_bib0200","doi-asserted-by":"crossref","first-page":"184","DOI":"10.12688\/f1000research.10416.1","article-title":"Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies","volume":"6","author":"Rupprecht","year":"2017","journal-title":"F1000 Res"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.biologicals.2014.04.001","article-title":"Replacing the NIH test for rabies vaccine potency testing: a synopsis of drivers and barriers","volume":"42","author":"Schiffelers","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI114260","article-title":"Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies","volume":"84","author":"Schumacher","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jviromet.2018.11.005_bib0215","series-title":"Laboratory Techniques in Rabies","first-page":"145","article-title":"Potency-test requirements of the United States national institute of health (NIH)","author":"Seligmann","year":"1966"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0220","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2013.05.081","article-title":"An electrochemiluminescence assay for analysis of rabies virusglycoprotein content in rabies vaccines","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.provac.2011.10.001","article-title":"Introduction and summary of the international workshop on alternative methods to reduce, refine, and replace the use of animals in vaccine potency and safety testing: state of the science and future directions","volume":"5","author":"Stokes","year":"2011","journal-title":"Proc Vaccinol"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0235","series-title":"Laboratory Techniques in Rabies","first-page":"360","article-title":"The NIH test for potency","author":"Wilbur","year":"1996"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0240","series-title":"OIE Terrestrial Manual. 2.1.13 Rabies","author":"World Organisation for Animal Health - OIE","year":"2008"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0245","series-title":"Recommendations for Inactivated Rabies Vaccine for Human Use Produced in Cell Substrates and Embryonated Eggs. WHO Technical Report Series, no. 941. Geneva","first-page":"109","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0250","series-title":"Recommendations for the Preparation, Characterization and Establishment of International and Other Biological Reference Standards. WHO Technical Report Series, No. 932, Geneva","author":"World Health Organisation","year":"2006"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0255","series-title":"Report No.: TRS 931","article-title":"WHO expert consultation on rabies, first report. Geneva, Switzerland","author":"World Health Organisation","year":"2005"},{"key":"10.1016\/j.jviromet.2018.11.005_bib0260","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0264-410X(91)90188-C","article-title":"The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines","volume":"9","author":"Wunderli","year":"1991","journal-title":"Vaccine"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016609341830380X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016609341830380X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T04:13:49Z","timestamp":1605413629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016609341830380X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":52,"alternative-id":["S016609341830380X"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2018.11.005","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}